U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H9Cl2N3O2
Molecular Weight 214.05
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARMUSTINE

SMILES

ClCCNC(=O)N(CCCl)N=O

InChI

InChIKey=DLGOEMSEDOSKAD-UHFFFAOYSA-N
InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)

HIDE SMILES / InChI
Molecular Formula C5H9Cl2N3O2
Molecular Weight 214.05
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/carmustine.html http://www.rxlist.com/bicnu-drug.htm http://www.wikidoc.org/index.php/Carmustine_(injection)

Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine.

CNS Activity

Originator

Approval Year

1977
76
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 57.0 µM [IC50]
Inhibitor
8504
Inhibitor
8504
 1.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Secondary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Secondary
Approved
8583
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/15077226
600 mg/m² 1 times / day steady-state, intravenous
dose: 600 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: Cyclophosphamide | Cisplatin
Cyclophosphamide | Cisplatin
 CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.8 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3719578
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
456 μg × min/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/15077226
600 mg/m² 1 times / day steady-state, intravenous
dose: 600 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: Cyclophosphamide | Cisplatin
Cyclophosphamide | Cisplatin
 CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
538 μM × min
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3719578
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18 min
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/15077226
600 mg/m² 1 times / day steady-state, intravenous
dose: 600 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: Cyclophosphamide | Cisplatin
Cyclophosphamide | Cisplatin
 CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
23%
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/3719578
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
unhealthy, 26-66
Health Status: unhealthy
Age Group: 26-66
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
DLT: Leukopenia, Thrombocytopenia...
Disc. AE: Pulmonary toxicity...
Dose limiting toxicities:
Leukopenia (grade 3-4, 45%)
Thrombocytopenia (grade 3-4, 27%)
AEs leading to
discontinuation/dose reduction:
Pulmonary toxicity (9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
125 mg/m2 1 times / 6 weeks multiple, intravenous
MTD
Dose: 125 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 125 mg/m2, 1 times / 6 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
unhealthy, 31-79
Health Status: unhealthy
Age Group: 31-79
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
DLT: Thrombocytopenia...
Disc. AE: Adult respiratory distress syndrome...
Dose limiting toxicities:
Thrombocytopenia (grade 3-4)
AEs leading to
discontinuation/dose reduction:
Adult respiratory distress syndrome (grade 5, 4.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Disc. AE: Marrow depression of, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Marrow depression of
Thrombocytopenia
Leukopenia
Pulmonary toxicity
Administration site extravasation
Carcinogenicity
Fetal damage
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Pulmonary toxicity 9%
Disc. AE
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
unhealthy, 26-66
Health Status: unhealthy
Age Group: 26-66
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
Thrombocytopenia grade 3-4, 27%
DLT
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
unhealthy, 26-66
Health Status: unhealthy
Age Group: 26-66
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
Leukopenia grade 3-4, 45%
DLT
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
unhealthy, 26-66
Health Status: unhealthy
Age Group: 26-66
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9457812
Thrombocytopenia grade 3-4
DLT
125 mg/m2 1 times / 6 weeks multiple, intravenous
MTD
Dose: 125 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 125 mg/m2, 1 times / 6 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
unhealthy, 31-79
Health Status: unhealthy
Age Group: 31-79
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
Adult respiratory distress syndrome grade 5, 4.2%
Disc. AE
125 mg/m2 1 times / 6 weeks multiple, intravenous
MTD
Dose: 125 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 125 mg/m2, 1 times / 6 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
unhealthy, 31-79
Health Status: unhealthy
Age Group: 31-79
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1531148
Administration site extravasation Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Carcinogenicity Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Fetal damage Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Leukopenia Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Marrow depression of Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Pulmonary toxicity Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Thrombocytopenia Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3423
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3423
ChemicalBook
CB0449612
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0449612
eMolecules
535644
https://www.emolecules.com/cgi-bin/more?vid=535644
MolPort
MolPort-003-665-505
https://www.molport.com/shop/molecule-link/MolPort-003-665-505
ZINC
ZINC000003830387
http://zinc15.docking.org/substances/ZINC000003830387
PubMed

PubMed

TitleDatePubMed
Up-regulation of K(+) channels in diabetic rat ventricular myocytes by insulin and glutathione.
2002-01
Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells.
2002-01
Induction of lacI mutations in Big Blue Rat-2 cells treated with 1-(2-hydroxyethyl)-1-nitrosourea: a model system for the analysis of mutagenic potential of the hydroxyethyl adducts produced by 1,3-bis (2-chloroethyl)-1-nitrosourea.
2001-12-12
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
2001-12
HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
2001-12
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
2001-11-15
The effectiveness of the O(6)-alkylguanine-DNA alkyltransferase encoded by the ogt(ST) gene from S. typhimurium in protection against alkylating drugs, resistance to O(6)-benzylguanine and sensitisation to dibromoalkane genotoxicity.
2001-10-18
Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity.
2001-10-12
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
2001-10
Outcome and long-term side effects after synchronous radiochemotherapy for childhood brain stem gliomas.
2001-10
G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
2001-10
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
2001-10
Induction of mild intracellular redox imbalance inhibits proliferation of CaCo-2 cells.
2001-10
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
2001-10
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
2001-10
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors.
2001-10
Quinacrine enhances carmustine therapy of experimental rat glioma.
2001-10
Use of pure t-butanol as a solvent for freeze-drying: a case study.
2001-09-11
[Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
2001-09
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
2001-09
Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
2001-09
T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement.
2001-09
Accelerated hazards regression model and its adequacy for censored survival data.
2001-09
Nitric oxide and free stable nitroxyl radicals in the mechanism of biological action of the spin-labeled compounds.
2001-09
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
2001-08
Temozolomide in combination with other cytotoxic agents.
2001-08
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
2001-08
[Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].
2001-07-24
Diaminopurine-acridine heterodimers for specific recognition of abasic site containing DNA. Influence on the biological activity of the position of the linker on the purine ring.
2001-07-23
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
2001-07-15
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
2001-07-10
Biodegradable polymer implants to treat brain tumors.
2001-07-06
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.
2001-07-01
Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.
2001-07
Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
2001-07
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
2001-07
Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
2001-07
Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.
2001-07
Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA.
2001-07
Modulation of 1,3-bis-(2-chloroethyl)-1-nitrosourea resistance in human tumor cells using hammerhead ribozymes designed to degrade O6-methylguanine DNA methyltransferase mRNA.
2001-07
Anticancer therapy by overexpression of superoxide dismutase.
2001-06
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
2001-06
Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
2001-05
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
2001-04
Pharmacodynamics of high-dose chemotherapy.
2001-03
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
2001-02
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
2001
Gamma-glutamyl transferase expression in higher-grade astrocytic glioma.
2001
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
2001
Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
2001
Patents

Patents

20010004454
41
JP2003175058A
13
JP2006502184A
41
JP2008533019A
34
JP2011528275A
456
JP2012500104A
108
JP4663232B2
15
JP4744875B2
29
JPH049338A
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: The recommended dose of carmustine is eight 7.7 mg wafers for a total of 61.6 mg implanted intracranially.
The recommended dose of BiCNU as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as 75 to 100 mg/m2 on 2 successive days.
Route of Administration: Other
In Vitro Use Guide
Sources: Doi:10.4236/nm.2011.24050
LD50 values for the short term glioma tumour cultures lay in the range 10 - 90 μg/ml for Carmustine.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:36:13 GMT 2025
Edited
by admin
on Mon Mar 31 17:36:13 GMT 2025
Record UNII
U68WG3173Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARMUSTINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BECENUN
Preferred Name English
CARMUSTINE [EP IMPURITY]
Common Name English
GLIADEL
Brand Name English
SRI-1720
Code English
BISCHLOROETHYL NITROSOUREA [IARC]
Common Name English
CARMUSTINE [JAN]
Common Name English
Carmustine [WHO-DD]
Common Name English
DTI-015
Code English
CARMUSTINE [EP MONOGRAPH]
Common Name English
SK-27702
Code English
CARMUSTINE [MI]
Common Name English
carmustine [INN]
Common Name English
CARMUSTINE [USAN]
Common Name English
CARMUSTINE [MART.]
Common Name English
UREA, N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-
Systematic Name English
CARMUSTINE [USP MONOGRAPH]
Common Name English
CAMUSTINE [VANDF]
Common Name English
CARMUSTINE [HSDB]
Common Name English
BICNU
Brand Name English
CARMUBRIS
Brand Name English
NSC-409962
Code English
FDA-0345
Code English
BCNU
Code English
CARMUSTINE [USP-RS]
Common Name English
CARMUSTINE [ORANGE BOOK]
Common Name English
1,3-Bis(2-chloroethyl)-1-nitrosourea
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C699
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
LIVERTOX NBK548307
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
FDA ORPHAN DRUG 37089
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
WHO-ATC L01AD01
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
NDF-RT N0000000236
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
NDF-RT N0000175558
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
WHO-VATC QL01AD01
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
FDA ORPHAN DRUG 606517
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
FDA ORPHAN DRUG 134500
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
EU-Orphan Drug EU/3/02/085
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
FDA ORPHAN DRUG 801420
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
Code System Code Type Description
DAILYMED
U68WG3173Y
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID8022743
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
INN
2959
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
FDA UNII
U68WG3173Y
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
WIKIPEDIA
CARMUSTINE
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
205-838-2
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
MESH
D002330
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
DRUG CENTRAL
512
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
NCI_THESAURUS
C349
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
PUBCHEM
2578
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
SMS_ID
100000090209
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
CHEBI
3423
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
IUPHAR
6800
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
MERCK INDEX
m3115
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB00262
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL513
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
RXCUI
2105
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY RxNorm
CAS
154-93-8
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
EVMPD
SUB06132MIG
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
RS_ITEM_NUM
1096724
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
LACTMED
Carmustine
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
HSDB
7761
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
NSC
409962
Created by admin on Mon Mar 31 17:36:13 GMT 2025 , Edited by admin on Mon Mar 31 17:36:13 GMT 2025
PRIMARY
Related Record Type Details
Structure of CARMUSTINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
EP
Structure of CARMUSTINE
BASIS OF STRENGTH->SUBSTANCE
solvent-free basis
ASSAY (HPLC)
USP
Related Record Type Details
Structure of 2-CHLOROETHYLAMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
Structure of 2-Chloroethanol
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Structure of Acetaldehyde
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Structure of 1,3-BIS(2-CHLOROETHYL)UREA
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of CARMUSTINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966